Merus N.V. (MRUS)
| Previous close | 44.93 |
| Open | 44.66 |
| Bid | 44.77 x 100 |
| Ask | 45.12 x 100 |
| Day's range | 44.00 - 45.19 |
| 52-week range | 18.21 - 52.03 |
| Volume | |
| Avg. volume | 601,454 |
| Market cap | 2.637B |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.00 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 60.83 |
ZacksMerus (MRUS) Moves 7.1% Higher: Will This Strength Last?
Merus (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ZacksWill Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know
Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globe NewswireMerus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation MCLA-129 in NSCLC with c-MET exon 14 skipping mutations initial interim clinical data selected for poster presentation UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (N
